148 related articles for article (PubMed ID: 3966916)
1. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.
Boobis AR; Murray S; Hampden CE; Davies DS
Biochem Pharmacol; 1985 Jan; 34(1):65-71. PubMed ID: 3966916
[TBL] [Abstract][Full Text] [Related]
2. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
[TBL] [Abstract][Full Text] [Related]
3. (+)-bufuralol 1'-hydroxylation activity in human and rhesus monkey intestine and liver.
Prueksaritanont T; Dwyer LM; Cribb AE
Biochem Pharmacol; 1995 Oct; 50(9):1521-5. PubMed ID: 7503805
[TBL] [Abstract][Full Text] [Related]
4. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
[TBL] [Abstract][Full Text] [Related]
5. Attempts to phenotype human liver samples in vitro for debrisoquine 4-hydroxylase activity.
Boobis AR; Hampden CE; Murray S; Beaune P; Davies DS
Br J Clin Pharmacol; 1985 Jun; 19(6):721-9. PubMed ID: 4027115
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
7. Bufuralol 1'-hydroxylase activity of the rat. Strain differences and the effects of inhibitors.
Boobis AR; Seddon CE; Davies DS
Biochem Pharmacol; 1986 Sep; 35(17):2961-5. PubMed ID: 3741485
[TBL] [Abstract][Full Text] [Related]
8. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism.
Distlerath LM; Reilly PE; Martin MV; Davis GG; Wilkinson GR; Guengerich FP
J Biol Chem; 1985 Jul; 260(15):9057-67. PubMed ID: 4019462
[TBL] [Abstract][Full Text] [Related]
9. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
[TBL] [Abstract][Full Text] [Related]
10. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
11. Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation.
Minder EI; Meier PJ; Müller HK; Minder C; Meyer UA
Eur J Clin Invest; 1984 Jun; 14(3):184-9. PubMed ID: 6147254
[TBL] [Abstract][Full Text] [Related]
12. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
Gut J; Gasser R; Dayer P; Kronbach T; Catin T; Meyer UA
FEBS Lett; 1984 Aug; 173(2):287-90. PubMed ID: 6146537
[TBL] [Abstract][Full Text] [Related]
13. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
14. Catalytic specificity of CYP2D isoforms in rat and human.
Hiroi T; Chow T; Imaoka S; Funae Y
Drug Metab Dispos; 2002 Sep; 30(9):970-6. PubMed ID: 12167561
[TBL] [Abstract][Full Text] [Related]
15. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling.
Wolff T; Distlerath LM; Worthington MT; Groopman JD; Hammons GJ; Kadlubar FF; Prough RA; Martin MV; Guengerich FP
Cancer Res; 1985 May; 45(5):2116-22. PubMed ID: 3921236
[TBL] [Abstract][Full Text] [Related]
16. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man.
Zanger UM; Vilbois F; Hardwick JP; Meyer UA
Biochemistry; 1988 Jul; 27(15):5447-54. PubMed ID: 3052575
[TBL] [Abstract][Full Text] [Related]
17. The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation.
Meyer UA; Gut J; Kronbach T; Skoda C; Meier UT; Catin T; Dayer P
Xenobiotica; 1986 May; 16(5):449-64. PubMed ID: 2874666
[TBL] [Abstract][Full Text] [Related]
18. Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.
Kronbach T
Methods Enzymol; 1991; 206():509-17. PubMed ID: 1686064
[No Abstract] [Full Text] [Related]
19. The role of CYP2C19 in the metabolism of (+/-) bufuralol, the prototypic substrate of CYP2D6.
Mankowski DC
Drug Metab Dispos; 1999 Sep; 27(9):1024-8. PubMed ID: 10460802
[TBL] [Abstract][Full Text] [Related]
20. Stereoselectivity in the oxidation of bufuralol, a chiral substrate, by human cytochrome P450s.
Narimatsu S; Takemi C; Kuramoto S; Tsuzuki D; Hichiya H; Tamagake K; Yamamoto S
Chirality; 2003 May; 15(4):333-9. PubMed ID: 12666241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
